Aytu Biopharma Inc (AYTU) Stock Price, Quote & News

Company Profile

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 720 437 6580

Website: aytubio.com

Address:

Denver Corporate Center III, Suite 920 7900 East Union Avenue, Denver, United States

Alain_Simard Nov. 15 at 12:05 AM

$AYTU calm down folks!!! You will all get a chance to average down at $0.50 shortly… you didn’t miss your opportunity!! 😂😂😂

0 · Reply

Telorino Nov. 14 at 10:13 PM

$AYTU never fails to disappoint! By the end of the day it dropped all the days gains…

0 · Reply

Butter_nutz Nov. 14 at 8:51 PM

$AYTU Everyone just remember... "...the stock price is what it is..." JD

0 · Reply

Henry20feb_ Nov. 14 at 9:35 AM

$AYTU Cash: $32.6M provides: Multi-quarter runway for the EXXUA launch / Buffer for sales force expansion and inventory buildup / Reduced need for near-term dilution or debt.

0 · Reply

Henry20feb_ Nov. 14 at 9:27 AM

$AYTU Net Income: $2.0M up from $1.5M YoY, showing improving operational efficiency despite higher spending on EXXUA launch preparation. Without EXXUA spending, it would have been the 10th consecutive positive adjusted EBITDA quarter.

0 · Reply

Wildsens Nov. 13 at 11:00 PM

$AYTU next: offering.

1 · Reply

Encept Nov. 13 at 10:41 PM

$AYTU

0 · Reply

Fibonacci5 Nov. 13 at 9:12 PM

$AYTU $35M cash on hand. Trading below cash value. Jsut the cash … not to count premium on drugs . Oh my 🚀

1 · Reply

Alain_Simard Nov. 13 at 6:05 PM

$AYTU 3 1/2 hours to go… the suspense is REAL. 😂😂😂😂

0 · Reply

Dolphinsarecute Nov. 13 at 5:33 PM

$AYTU 41k followers, wow. This must definitely be a great stock, company and ceo. Warning bells? Nope, not a single one. Recommendation: Go all in!

1 · Reply

Aytu BioPharma, Inc. (AYTU) Q1 2026 Earnings Call Transcript

Nov 13, 2025, 4:05 PM EST - 1 day ago

Aytu BioPharma Reports Fiscal 2026 First Quarter Operational and Financial Results

Nov 5, 2025, 4:05 PM EST - 9 days ago

Aytu BioPharma to Report Fiscal 2026 First Quarter Operational and Financial Results on November 13, 2025

Oct 28, 2025, 9:00 AM EDT - 17 days ago

Aytu BioPharma Announces Patent Term Extension for EXXUA(TM)

Oct 10, 2025, 9:00 AM EDT - 5 weeks ago

Aytu BioPharma to Present at Upcoming October 2025 Conferences

Sep 24, 2025, 4:15 PM EDT - 7 weeks ago

Aytu BioPharma to Present at Upcoming September 2025 Conferences

Sep 23, 2025, 9:43 PM EDT - 7 weeks ago

Aytu BioPharma, Inc. (AYTU) Q4 2025 Earnings Call Transcript

Sep 23, 2025, 4:05 PM EDT - 7 weeks ago

Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)

Sep 16, 2025, 4:05 PM EDT - 2 months ago

Aytu BioPharma to Report Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results on September 23, 2025

Jun 25, 2025, 8:00 AM EDT - 5 months ago

Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)

Jun 23, 2025, 8:00 AM EDT - 5 months ago

Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

Jun 9, 2025, 4:30 PM EDT - 5 months ago

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan

Jun 6, 2025, 8:01 AM EDT - 5 months ago

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

Jun 6, 2025, 8:00 AM EDT - 5 months ago

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

May 14, 2025, 8:29 PM EDT - 6 months ago

Aytu BioPharma, Inc. (Aytu ) Q3 2025 Earnings Call Transcript

May 14, 2025, 4:05 PM EDT - 6 months ago

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results

May 7, 2025, 4:15 PM EDT - 6 months ago

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational and Financial Results on May 14, 2025

Apr 21, 2025, 4:05 PM EDT - 7 months ago

Aytu BioPharma to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025

Feb 12, 2025, 6:27 PM EST - 9 months ago

Aytu BioPharma, Inc. (AYTU) Q2 2025 Earnings Call Transcript

Feb 12, 2025, 4:03 PM EST - 9 months ago

Aytu BioPharma Reports Fiscal 2025 Second Quarter Operational and Financial Results

Feb 5, 2025, 5:50 PM EST - 10 months ago

Aytu BioPharma to Report Fiscal 2025 Second Quarter Operational and Financial Results on February 12, 2025

Jan 6, 2025, 9:00 AM EST - 11 months ago

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Dec 3, 2024, 11:45 PM EST - 1 year ago

Aytu BioPharma Disclosure Notification

Nov 22, 2024, 9:00 AM EST - 1 year ago

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM)

Nov 13, 2024, 7:25 PM EST - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q1 2025 Earnings Call Transcript

Nov 13, 2024, 4:05 PM EST - 1 year ago

Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results

Nov 6, 2024, 5:20 PM EST - 1 year ago

Aytu BioPharma to Report Fiscal 2025 First Quarter Operational and Financial Results on November 13, 2024

Oct 14, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada

Sep 26, 2024, 6:51 PM EDT - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q4 2024 Earnings Call Transcript

Sep 26, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results

Sep 19, 2024, 5:30 PM EDT - 1 year ago

Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024

Aug 8, 2024, 5:20 PM EDT - 1 year ago

Aytu BioPharma to Participate in the Sidoti Micro-Cap Virtual Conference on August 14-15, 2024

Aug 6, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations

Jun 18, 2024, 8:00 AM EDT - 1 year ago

Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms

May 15, 2024, 8:28 PM EDT - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript

May 15, 2024, 4:05 PM EDT - 1 year ago

Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results

May 8, 2024, 4:15 PM EDT - 1 year ago

Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024

Apr 3, 2024, 9:00 AM EDT - 1 year ago

Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024

Feb 14, 2024, 10:52 PM EST - 1 year ago

Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript

Feb 14, 2024, 4:05 PM EST - 1 year ago

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Feb 7, 2024, 4:15 PM EST - 1 year ago

Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024

Jan 23, 2024, 9:00 AM EST - 1 year ago

Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

Nov 30, 2023, 8:00 AM EST - 2 years ago

Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023

Nov 14, 2023, 7:30 PM EST - 2 years ago

Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript

Nov 14, 2023, 4:05 PM EST - 2 years ago

Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results

Nov 8, 2023, 8:30 AM EST - 2 years ago

Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year

Nov 7, 2023, 4:15 PM EST - 2 years ago

Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023

Oct 26, 2023, 8:00 AM EDT - 2 years ago

Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement

Oct 9, 2023, 4:15 PM EDT - 2 years ago

Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023

Alain_Simard Nov. 15 at 12:05 AM

$AYTU calm down folks!!! You will all get a chance to average down at $0.50 shortly… you didn’t miss your opportunity!! 😂😂😂

0 · Reply

Telorino Nov. 14 at 10:13 PM

$AYTU never fails to disappoint! By the end of the day it dropped all the days gains…

0 · Reply

Butter_nutz Nov. 14 at 8:51 PM

$AYTU Everyone just remember... "...the stock price is what it is..." JD

0 · Reply

Henry20feb_ Nov. 14 at 9:35 AM

$AYTU Cash: $32.6M provides: Multi-quarter runway for the EXXUA launch / Buffer for sales force expansion and inventory buildup / Reduced need for near-term dilution or debt.

0 · Reply

Henry20feb_ Nov. 14 at 9:27 AM

0 · Reply

Wildsens Nov. 13 at 11:00 PM

$AYTU next: offering.

1 · Reply

Encept Nov. 13 at 10:41 PM

$AYTU

0 · Reply

Fibonacci5 Nov. 13 at 9:12 PM

$AYTU $35M cash on hand. Trading below cash value. Jsut the cash … not to count premium on drugs . Oh my 🚀

1 · Reply

Alain_Simard Nov. 13 at 6:05 PM

$AYTU 3 1/2 hours to go… the suspense is REAL. 😂😂😂😂

0 · Reply

Dolphinsarecute Nov. 13 at 5:33 PM

$AYTU 41k followers, wow. This must definitely be a great stock, company and ceo. Warning bells? Nope, not a single one. Recommendation: Go all in!

1 · Reply

Chachix Nov. 13 at 1:25 PM

$AYTU CASINO on FRAUDULENT MARKETS!!!

0 · Reply

Henry20feb_ Nov. 13 at 9:12 AM

$AYTU New institutional holders are entering the AYTU-block, and mutual fund holders are increasing their share sizes. 🥳

0 · Reply

Henry20feb_ Nov. 13 at 8:45 AM

$AYTU AYTU will report its operational and financial results for its first quarter of fiscal 2026, after the market close on Thursday, November 13, 2025.

0 · Reply

GoWhiteSox Nov. 13 at 12:36 AM

$AYTU Will AYTU beat quarterly earning estimates? I say no! They haven’t said a word about sales of EXXUA. It was supposed to happen in this quarter. They only have a few weeks left this year. AYTU management continues to overpromise and underdeliver since it’s inception!!

2 · Reply

Henry20feb_ Nov. 12 at 9:34 PM

$AYTU Quote: "It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance." (Benzinga 2025 / no investment advise).

0 · Reply

Looking_For_Gems_444 Nov. 11 at 8:32 PM

$AYTU There is no way anyone is actually bullish on this company. Was here 4 years ago. This will never go anywhere but down

2 · Reply

Henry20feb_ Nov. 7 at 9:03 AM

$AYTU To paint a picture: Aytu's current (fully diluted) P/S ~0.52× (Extremely low, roughly one-tenth of the sector median). However, to sustain higher multiples, Aytu must show revenue growth, positive operating leverage, and limited further dilution.

1 · Reply

GATTACA2025 Nov. 7 at 8:07 AM

$AYTU dishbrow bros yikes

0 · Reply

WendyMorell1077 Nov. 6 at 4:04 PM

$AYTU trades in a tight range as investors anticipate updates. AITX capitalizes on growth opportunities with proven autonomous AI for asset protection.

1 · Reply

Henry20feb_ Nov. 6 at 3:53 PM

$AYTU Probably a crashed russian drone.

0 · Reply

Henry20feb_ Nov. 6 at 9:12 AM

$AYTU The (few) analists consensus earnings per share (EPS) estimate for Q1 FY 2026 is about –$0.19. For revenue, the estimate is roughly $12.6 million (low ~ $12.18 m, high ~ $13.5 m). Let's see 😨

0 · Reply

Ironman96 Nov. 6 at 12:29 AM

$AYTU The morons on this board are gonna find out soon.

0 · Reply

Market Cap	20.99M
Revenue (ttm)	66.38M
Net Income (ttm)	-13.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-20.43%
Debt to Equity Ratio	1.15

Volume	154,100
Avg Vol	212,994
Day's Range	N/A - N/A
Shares Out	10.19M
Stochastic %K	54%
Beta	0.25
Analysts	Sell
Price Target	$9.17